14-May-2026
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Business Wire (Thu, 14-May 4:00 PM ET)
Adicet Bio Sees Reduced Losses and Lower Spending as Key Clinical Milestones Near
Market Chameleon (Thu, 14-May 7:50 AM ET)
Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET) and Doximity (DOCS)
TipRanks (Thu, 14-May 9:00 AM ET)
Wedbush Sticks to Its Buy Rating for Adicet Bio (ACET)
TipRanks (Thu, 14-May 8:33 AM ET)
Canaccord Genuity Remains a Buy on Adicet Bio (ACET)
TipRanks (Thu, 14-May 7:22 AM ET)
Adicet Bio GAAP EPS of -$1.88 beats by $1.20
Seeking Alpha News (Wed, 13-May 4:49 PM ET)
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Business Wire (Wed, 13-May 4:01 PM ET)
Business Wire (Thu, 12-Mar 4:00 PM ET)
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Adicet Bio trades on the NASDAQ stock market under the symbol ACET.
As of May 14, 2026, ACET stock price climbed to $8.41 with 152,809 million shares trading.
ACET has a beta of 1.92, meaning it tends to be more sensitive to market movements. ACET has a correlation of 0.14 to the broad based SPY ETF.
ACET has a market cap of $78.62 million. This is considered a Micro Cap stock.
In the last 3 years, ACET traded as high as $116.48 and as low as $6.01.
The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, VXF, DFAS, DFMC.
ACET has underperformed the market in the last year with a return of -18.5%, while SPY returned +28.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ACET shares. However, ACET has outperformed the market in the last 3 month and 2 week periods, returning +21.7% and +11.4%, while SPY returned +10.0% and +4.1%, respectively. This indicates ACET has been having a stronger performance recently.
ACET support price is $7.65 and resistance is $8.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET shares will trade within this expected range on the day.